I'm looking for

All Events

Abstract Information

Submit Abstracts, Trials in Progress, Surgical Films and Late-Breaking Abstract Shells for the SGO 2027 Annual Meeting on Gynecologic Cancer

Call for Abstracts, Trials in Progress, Surgical Films, and Late-Breaking Abstract Shells is open from July 13 – September 18, 2026, at 11:59 pm CST 

 

 

Table of Contents 
Regular Abstracts   Late-Breaking Abstracts 
Submission Eligibility Submission Eligibility
Submission and Author Requirements Submission Shell Requirements
Steps for Submission Review Criteria
Review Criteria and Timeline Timeline
Frequently Asked Questions
Defining the Next Era

The SGO 2027 Annual Meeting theme is “Defining the Next Era.” Submitters are encouraged to propose innovative ideas that align with this vision, focusing on the following key concepts:

  1. Clinical Trials/Novel Therapeutics
  2. Surgical Techniques & Outcomes 
  3. Disparities & Population Health 
  4. Translational Science & Biomarkers 
  5. Patient Consideration & Survivorship 
  6. Prevention & Genetics 
  7. Clinical Outcomes and Quality Metrics 

Only one Key Concept category must be selected which best represents the content of the submission. Multiple disease sites may be selected as follows: 

  • Ovarian 
  • Uterine 
  • Cervical 
  • Vaginal, Vulvar & GTN 
  • Rare Tumor  
Submission Types
  • Abstract: Innovative science covering a range of topics that are relevant to gynecologic oncology 
  • Late-Breaking Abstract Shells: High-impact, groundbreaking science 
  • Trials in Progress (TIP) Posters: Typically slotted as a poster; ongoing research without available data results  
  • Surgical Film: Documents a surgical procedure, serves as an instructional tool.    

Submit Abstracts, Trials in Progress, surgical films

Abstracts, Trials in Progress Posters, and Surgical Films: 

Submission Eligibility 
  • SGO does not cover registration fees, travel, or related expenses.  
  • Submission does not require fees, sponsorship, or SGO membership.  
  • SGO may decline or withdraw abstracts at its discretion.  
  • Submissions may cover any topic aligned with SGO’s mission; Key Concepts support peer review and are not restrictive.  
  • Submissions must present new, unpublished, and previously unpresented science for the SGO 2027 Annual Meeting (March 19–22, 2027), except Trials in Progress and Surgical Films. Previously presented or ongoing work may be considered only if it includes significant new findings and is approved by the SGO 2027 Annual Meeting Program Committee. 
Submission Requirements 
  • SGO reserves the right to use an editor to check for errors and make minor updates.  
  • Each Abstract Submission must clearly identify the following:  
    • Title: Describe the nature of the content but does not include author or affiliation identifying terms. Use sentence case and capitalize only the first word and proper nouns.
      • Example: Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study 
    • Objectives: An introductory sentence indicating the purpose of the study  
    • Methods: A brief description of pertinent experimental procedures, including statistics 
    • Results: A summary of the new, unpublished data 
    • Conclusions: A statement of the conclusions 
  • Character Limit: 3,000 characters, including spaces; this does not include abstract title, author string, nor a single allotted table or graph.  
  • Institution Names and Location: Abstract text must be anonymous for grading purposes. Do not reference institution names or locations in the body of your abstract. 
  • No Use of Brand Names and Trade Names in Submissions: Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract.  
  • Table/Graph: Each abstract submission is limited to one (1) table or graph. Do not enter charts, graphs, bullet points, indentations, or references in the abstract text.  
  • Language Format and Grammar: Text must be in English. Review your abstract for grammar and spelling errors prior to submitting. 
  • Surgical Film Submissions: 
    • Evaluated based on educational content and audio/visual quality. 
    • No longer than 10 minutes
    • Must include sound and run at normal speed in  .mp3, .avi, .mov, .mpg, .mp4, or .m4a; MP4 preferred (≤200 MB)  
Presenting Author Requirements 
  • Submission Categories: A submission may be submitted using the Presenting Author, or Author categories; only one Presenting Author can be indicated and will be listed first.
  • Multiple Abstracts and Surgical Films: A presenting author may submit multiple abstracts; however, presentations cannot occur at the same time, unless designated as on-demand/virtual or another author is reassigned as the presenting author.  
  • Use consistent contact information across submissions.  
  • Duplicate submissions of the same abstract or surgical film are not allowed.  
  • Authorship: Maximum of 25 authors per abstract; contact education@sgo.org if exceeded.  
  • Authors must include full names, credentials (MD, PhD, etc.), and location (city/state/country).  
  • Responsibilities: Submitters add authors in the database, set author order for final publication, and send bio/COI invitations. 
Steps for Submission 
  • Select only one Key Concept Group category. Select as many disease sites as are applicable.
  • Complete all required fields and submit before the deadline. Confirmation emails will be sent upon successful submission. 
  • Edits are permitted only until the submission deadline. 
  • Contact SGO Education Department at education@sgo.org for questions. 
Review Criteria and Timeline 

Review Criteria

Submissions are peer-reviewed for scientific merit, quality, advanced, and innovative methods.

Timeline

  • Regular Call for Abstracts, Trials in Progress, and Surgical Films Timeline: 
    • Monday, July 13, 2026 – Abstract and Surgical Film Submission Opens
    • Friday, September 18, 2026– Abstracts, Trials in Progress, and Surgical Film Submission Deadline
    • Early December 2026 (date subject to change) – Notifications of Acceptance; Poster notifications may be delayed due to batch number assignments
    • Mid-December 2026 – Presenting Authors Complete Required Presentation Acceptance Survey
    • Tuesday, January 5, 2027 – Presenting Authors Complete Disclosures and Register for the Meeting
    • Tuesday, February 2, 2027 – After Abstract Acceptance: Withdraw or Reassign Presenting Author
    • Tuesday, February 9, 2027 – Upload PowerPoint Presentation (using the official SGO template) and ePoster (PDF version of your poster, also using the SGO template)

SuBmIt Abstracts, Trials in progress, And Surgical films

 

Late-Breaking Abstracts

The Late-Breaking Abstract (LBA) shell submission process is designed for high-impact, emerging research not ready for full submission by the regular deadline. Selected submissions will be invited to complete full abstract details by January 2027. We encourage presenting authors with timely, innovative work to take advantage of this opportunity and submit an LBA shell for consideration.

Late-Breaking Abstracts (LBAs) Definition: 

  • Late-breaking abstract designation must feature high-impact research findings that are not available by the regular abstract submission. 
  • SGO will only accept LBAs of randomized trials or original research showcasing innovative studies with significant, practice-changing impact. 
  • LBA designation is not a means for extending the regular abstract deadline. All studies that have complete data should be submitted as a regular abstract for consideration. 

Eligibility:

  • SGO does not cover registration fees, travel, or related expenses.  
  • Submission does not require fees, sponsorship, or SGO membership.  
  • SGO may decline or withdraw abstracts at its discretion. 
Submission Shell Requirements for Late-Breaking Abstracts 
  • Each Abstract Submission must clearly identify the following:  
    • Title: Describe the nature of the content but does not include author or affiliation identifying terms. Use sentence case and capitalize only the first word and proper nouns.
      • Example: Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study 
    • Introduction: A brief statement about the purpose of the study and its pertinent background.
    • Objectives: An introductory sentence indicating the purpose of the study  
    • Methods: A brief description of pertinent experimental procedures, including statistics 
    • Expected Results: If available, include any preliminary findings or anticipated analyses and data to be reported.
    • Impact: Briefly describe the study’s potential implications and its significance to the field.
  • Character Limit: 3,000 characters, including spaces; this does not include abstract title, author string, nor a single allotted table or graph.  
  • Institution Names and Location: Abstract text must be anonymous for grading purposes. Do not reference institution names or locations in the body of your abstract. 
  • No Use of Brand Names and Trade Names in Submissions: Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract.  
  • Table/Graph: Each abstract submission is limited to one (1) table or graph. Do not enter charts, graphs, bullet points, indentations, or references in the abstract text.  
  • Language Format and Grammar: Text must be in English. Review your abstract for grammar and spelling errors prior to submitting. 
  • Authorship: AI may be used only for grammar/readability, not authorship.
Review Criteria 

Submissions will be peer-reviewed and evaluated based on: 

  • Scientific merit and originality
  • Significance to the field 
  • Clarity of data and conclusions 
Late-Breaking Abstract Timeline 
  • Monday, July 13, 2026 – Late-Breaking Abstract Shell Submission Opens 
  • Friday, September 18, 2026 – Late-Breaking Abstract Shell Submission Deadline 
  • Early November 2026 – Late-Breaking Abstract Shell Selection Notifications 
  • Mid-November 2026 – Complete Late-Breaking Abstract Shell Selection Survey   
  • Tuesday, January 5, 2027 – Upload Final Submission Details 
  • Mid-January 2027 – Notifications of Acceptance for Final Round  
  • Late January 2027 – Complete Late-Breaking Abstract Required Presentation Acceptance Survey 
  • Wednesday, January 27, 2027 – Presenting Authors Complete Disclosures and Register for the Meeting  
  • Tuesday, February 2, 2027 – After Abstract Acceptance: Withdraw or Reassign Another Presenting Author 
  • Tuesday, February 16, 2027 – Upload PowerPoint Presentation (using the official SGO template) and Complete all Required Tasks in the Speaker Portal. 

Additional Information and FAQs 

  • An author may submit more than one late-breaking abstract 
  • Shell submissions that do not meet the criteria will not be reviewed 

To ensure a fair review process, authors intending to submit an late-breaking abstract must submit a shell abstract by Friday, September 18, 2026, at 11:59 pm CST.  

 

View FAQs for the SGO 2027 Annual Meeting Call for Abstracts, Surgical Films, Trials in Progress and Late-Breaking Abstracts.

Please contact SGO’s education department at education@sgo.org with any additional questions.

 

SGO 2027 Annual Meeting on Gynecologic Oncology Commercial Interests, Disclosure, Copyright, and Embargo Rules 

Abstracts and Surgical Films Sponsored by Commercial Interests 

  • An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit accme.org/standards.
  • Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds. 
  • Presenters and distillants will not accept any honoraria, additional payments or reimbursements directly from a commercial interest for my participation in this activity. 
  • The presenting author of an abstract must NOT have a relevant/specific ownership interest, i.e., owner, founder, partner, etc., in the scientific content in the abstract. If a conflict of interest exists, the abstract must be presented by a co-author with no relevant ownership interests. 
  • If the presenting author is employed by an ineligible company, as defined above, an alternate presenter must be named. 

Disclosure Rules  

  • Presenters are required to provide disclosure of relationships with commercial interests. 
  • Presenters are required to provide a balanced view of therapeutic options. 

Copyright Policy and Presentation Use 

By submitting an abstract or presenting at the SGO Annual Meeting, authors and presenters agree to to the subsequent Copyright Policy: 

  • SGO will own the copyright for the audio/visual recording of oral presentations, slide decks, and/or digital ePosters, once presented at the meeting, which may be packaged/sold at SGO’s sole discretion. Please contact education@sgo.org to obtain written permission to use these assets outside of the context of the SGO 2027 Annual Meeting. 
  • Presentations will be available online through the SGO Annual Meeting Event Platform for 60 days following the meeting. Selected content will be uploaded to the SGO ConnectEd platform following that date. 

Exceptions may apply where: 

  • One or more authors are employees of the United States federal government acting within the scope of their official duties  
  • Applicable law prohibits copyright transfer
  • Institutional or funding-agency requirements mandate alternative copyright arrangements approved in writing by SGO. 

Author Rights and Permitted Reuse 

Subject to acknowledgment of SGO copyright ownership, authors retain the nonexclusive right to: 

  • Reuse the abstract in future scholarly manuscripts or full-length journal articles;  
  • Include the abstract in dissertations, theses, grant applications, or academic portfolios;  
  • Reproduce the abstract for educational or teaching purposes;  
  • Share copies with colleagues for noncommercial scientific use;  
  • Post the abstract on personal, institutional, or noncommercial repositories after official publication by SGO;  
  • Present the data orally at scientific or educational meetings; and  
  • Incorporate the abstract content into future derivative scholarly works authored by the submitting authors.  

Any permitted reuse must include the following acknowledgment: © Society of Gynecologic Oncology (Year). Reproduced with permission. 

Authors are encouraged to link to the official SGO publication or meeting abstract page when feasible. 

Embargo Rules 

Abstracts submitted to the SGO Annual Meeting, including late-breaking abstract placeholders, are confidential and embargoed until SGO publishes the abstract online. Study data subsequently submitted for late-breaking abstracts are likewise confidential and embargoed. For data previously presented or published under an exemption, the Policy applies only to new or updated data in the abstract. 

SGO requires all abstract authors and news media to abide by the following embargo times for reporting on oral abstracts and poster presentations: 

  • For oral PowerPoint presentations, the embargo lifts  at 8am ET of the day on which the presentation is made. 
  • For all poster presentations and surgical films, the embargo is lifted at 8am ET on the first day of the meeting 
  • Session titles and times, presentation titles, and author names are embargoed until they are made publicly available by SGO. 
  • Full abstracts for oral and poster presentations shall be made available to registered attendees up to two weeks before the meeting. 
  • Full abstracts may be made available to the approved news media upon individual request in advance of the meeting provided they agree to abide by the embargo policy and approval by SGO. 

Use of Artificial Intelligence (AI) in Abstract Preparation 

SGO permits the limited use of artificial intelligence (AI) tools in the preparation of abstracts. Authors are expected to prepare the original scientific content and draft the abstract themselves. AI tools may be used to assist with language refinement, grammar, syntax, or organizational clarity. 

All data submitted must derive from legitimate research activities and must not be fabricated, manipulated, or generated by AI.  

Plagiarism Policy 

By submitting an abstract to the SGO Annual Meeting, you are attesting that your submission is free from plagiarism, as defined by any of the following: 

  • Direct: Intentionally submitting another person’s words or ideas verbatim as one’s own. 
  • Self-plagiarism: Submitting work that has been previously published or presented. 
  • Mosaic plagiarism: Stringing together portions of text from other sources; and 
  • Lack of attribution: Failing to appropriately identify and cite sources for language or ideas that are incorporated. 

Screening process: SGO screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of potentially plagiarized content will be evaluated by SGO staff and appropriate actions taken.